LivaNova PLC Net Change in Cash
LivaNova PLC (LIVN) reported Net Change in Cash of -$118.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$95.85M, a 744.08% decline year-over-year.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $14.88M, a 60.64% decline year-over-year.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $37.81M, a 415.14% increase year-over-year.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $7.34M, a 96.87% decline year-over-year.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$88.00M, a 160.41% decline from fiscal 2024.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $145.68M, a 134.02% increase from fiscal 2023.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $62.25M, a 79.76% decline from fiscal 2022.
- LivaNova PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $307.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$118.93M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$95.85M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$88.00M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$77.48M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$129.92M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $14.88M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $145.68M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $88.70M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $55.25M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $37.81M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $62.25M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $17.10M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $18.74M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $7.34M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $307.63M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $298.29M 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | $198.78M 10-Q · filed 2023-07-26 | |||
| 2022-03-31 | $234.39M 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | -$44.84M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$70.99M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $76.55M 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | -$293.00K 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $191.69M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $166.67M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $171.41M 10-Q · filed 2021-07-28 | |||
| 2020-03-31 | $64.69M 10-Q · filed 2021-04-28 | |||
| 2019-12-31 | $13.93M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $28.11M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | -$2.69M 10-Q · filed 2020-07-29 | |||
| 2019-03-31 | $3.57M 10-Q · filed 2020-04-30 | |||
| 2018-12-31 | -$46.41M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$13.67M 10-Q · filed 2019-10-30 | |||
| 2018-06-30 | -$46.23M 10-Q · filed 2019-07-31 | |||
| 2018-03-31 | -$28.65M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $53.83M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |